Latest Share Chat

REMOVE ADS

probiotix health Share Chat (PBX.PL)

probiotix health Information

Share Price Information for probiotix health (PBX.PL)

Share Price is delayed by 15 minutes

Get Live Data

7.875 0.125 (1.61%)

Bid:

7.25

Ask:

8.50

Spread: 1.25 (17.241%)

Market Cap: £12.46m

Last checked at -

Intraday probiotix health Share Chart

REMOVE ADS

Some Videos You Might Like

What's Hot as conflict cont...

10th March 2026

What's Hot during War

3rd March 2026

Lloyds

This chat board is for this share's listing on the Aquis Stock Exchange.

Chat Filters

You must be logged in to use filters Click here to login

Post Message

Post a Message

You must be logged in to post Click here to login

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".

By posting on our share chat boards you are agreeing to the following:

You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
- discuss illegal or criminal activities.
- post any confidential or price sensitive information or that is not public knowledge.
- post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
- post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
- post any personal details (e.g. email address or phone number).
- post live price or level 2 updates.
- publish content that is not your original work, or infringes the copyright or other rights of any third party.
- post non-constructive, meaningless, one word (or short) non-sense posts.
- post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
- post any affiliate or referral links, or post anything asking for a referral.
- post or otherwise publish any content unrelated to the board or the board's topic.
- re-post premium share chat posts on regular share chat.
- restrict or inhibit any other user from using the boards.
- impersonate any person or entity, including any of our employees or representatives.
- post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
- If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.

The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.

Please note some users may not behave properly and may post content that is misleading, untrue or offensive.

It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.

Premium and Verified Members

Premium Members are members that have a premium subscription with London South East. You can subscribe here.

London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.

Only showing the five most recent posts. Click here to view the whole thread.

REMOVE ADS

Only showing the five most recent posts. Click here to view the whole thread.

January 14, 2026 5:00 AM EST

Findings reflect the rigorous clinical standards behind DS-01®'s position as the #1 digestive health probiotic in the U.S.

LOS ANGELES, Jan. 14, 2026 /PRNewswire/ -- Microbiome science company Seed Health today announced the publication of new clinical findings in Nutrients demonstrating that its flagship innovation, DS-01® Daily Synbiotic, significantly reduces bloating, gas, and abdominal discomfort, while improving bowel regularity and digestive quality of life in otherwise healthy adults. The study represents the largest randomized, placebo-controlled probiotic or synbiotic clinical trial evaluating bloating, including both women and men, and the largest conducted in a non-patient population. The findings underscore the clinical foundation behind DS-01®'s position as the #1 digestive health probiotic in the United States.

"Bloating is one of the most common — and disruptive — gastrointestinal complaints, yet many people quietly self-manage without ever seeing a clinician," said Zain Kassam, M.D., M.P.H., Chief Medical Officer at Seed Health. "By studying DS-01® in a diverse, real-world population, we were able to show that meaningful relief is possible for otherwise healthy individuals who are often underrepresented in clinical research."

DS-01® Reduces Bloating, Improves Digestive Regularity

Participants taking DS-01® experienced statistically significant improvements in key symptoms compared to placebo over the six-week study period, including:

Reduced bloating + gas: Overall, nearly three-quarters of participants taking DS-01® reported bloating as never or rarely occurring at study end (p ; among those with mild-to-moderate bloating at baseline, 91% reported little to no interference from bloating in daily life as early as week one (p

Improved digestive regularity: Nearly 80% of participants taking DS-01® reported no or only slight constipation-related discomfort, along with improvements in stool regularity and the quality of bowel movements

Reduced abdominal discomfort: By the end of the study, 76% of participants reported abdominal pain (non-chronic) never or only rarely occurring (p

Improved quality of life: Participants reported less food avoidance and greater enjoyment of food (p , as well as fewer disruptions to daily activities due to digestive concerns

Improvement of anxiety-related feelings: In a subgroup of participants with mild, occasional baseline anxiety, 66% of those taking DS-01® report improvement in anxiety-related feelings

to follow

The accounting entry cost of £753k relating to share options is due to the Directors options and 5,250,000 to employees

S P O’Hara -3,000,000 0.210

M Caspani - -500,000 0.210

A Reynolds - 1,000,000 0.210

S Andersen - 5,000,000 0.095

The share options held by S P O’Hara, and A Reynolds were granted on 31 March 2022 and are exercisable at £0.21 at any time up 30 March 2032, 50% of which vest on a doubling of the share price to £0.42 and 50% on an annual turnover of £2.5m.

The share options held by M Caspani were granted on 31 March 2022 and are exercisable at £0.21 at any time up 30 March 2032, 1/3 of which vest on each of the 2-4 anniversaries of the date of grant.

The share options held by S Andersen were granted on 10 February 2025 and are exercisable at £0.095 at any time up 18 February 2035 50% vest when annual turnover reaches £2.5m, 50% vest on annual turnover of £5m.

so turnover of £2.5m achieved therefore a number have vested - though obviously won't be exercised yet at our current sp

in addition to the above employees have 5,250,000 options which basically vest again at £2.5m and £5m turnover and 9.5p

5,000,000 options vest as to 50% on a doubling of the share price to £0.42 and 50% on an annual turnover of £2.5m;

500,000 options, 1/3 of which vest on each of the 2-4 anniversaries of the date of grant; and

9,250,000 options vest as to 50% on an annual turnover of £2.5m and 50% on an annual turnover of £5m

now 20 Feb 2025 rns

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that options ("Options") have been granted over a total of 9,050,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") to Steen Andersen, Chief Executive of ProBiotix, and certain other key employees of the Company.

The options were granted on 19 February 2025 with an exercise price of 9.5p per share. The Options may be exercised within 10 years from the date of their grant, subject to satisfaction of commercially oriented performance criteria, which includes significant revenue targets.

Option holders can only exercise Options once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.

apparently 2.5m and 5m are significant revenue targets!

similar to rns 13 oct with 700,000 granted to employees

Must be one of the easiest targets to reach and a vesting price under 50% of original issue price

jees

mol

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

Thx to Dr_Horrible on another board

BEIJING -- China aims to increase the average life expectancy of its people to around 80 years through efforts planned for a five-year period from 2026 to 2030, announced the country's top health official on Friday.

By the end of 2024, the average life expectancy of the Chinese people had reached 79 years — an extraordinary achievement among developing countries, said Lei Haichao, head of the National Health Commission.

According to Lei, China has established the world's largest health service system, disease prevention and control system, and medical insurance system over the past five years, marking remarkable progress in the country's healthcare and population development.

China has also weathered a once-in-a-century pandemic and continuously improved its people's average life expectancy during the 14th Five-Year Plan period (2021-25), the official said.

"Based on the international development trend, the comprehensive national strength and work foundation of China, we hope to raise the average life expectancy of the Chinese population by one year in five years," the official added.

By the end of 2024, the number of elderly people aged 60 and above in China had reached 310.31 million, accounting for 22 percent of the country's total population.

On Thursday, the 20th Communist Party of China (CPC) Central Committee concluded its fourth plenary session, where participants deliberated and adopted the Recommendations of the CPC Central Committee for Formulating the 15th Five-Year Plan for Economic and Social Development.

The document requires enhancing both life expectancy and the overall health of the people.

Introducing work plans for the next five years, Lei vowed to improve elderly care by optimizing basic elderly care services, advancing long-term care insurance, upgrading support for elderly people with disabilities or dementia, and expanding rehabilitation and palliative care services.

According to statistics released by the Ministry of Civil Affairs this October, by the end of last year, the country also had 406,000 elderly care institutions and facilities with nearly 8 million beds, while various financial subsidies had benefited 49.45 million seniors.

In order to help Chinese people live healthier, higher-quality lives with longer life expectancy, Lei noted that disease prevention will be a key focus of China's health sector.

"Efforts will be made to advance family doctor services, to boost health knowledge promotion, and to effectively control weight, blood pressure, blood lipids and blood glucose, so that every individual can be master of their own health," Lei said.

He added that medical institutions will explore effective ways to treat chronic diseases such as cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes.

mol